- Monaghan Medical presents poster revealing possible under-dosing by continuous nebulizers at varying breathing patterns
PLATTSBURGH, NY., October 28, 2014 – Monaghan Medical announced today that the following study data will be presented during the American College of Chest Physicians Annual Conference in Austin, Texas, October 25 through October 30, 2014. The data will be presented via oral and poster presentations as follows:
- Monaghan Medical releases Robarts Research Institute study confirming Aerobika® OPEP device provides drug-free relief for COPD patients
PLATTSBURGH, NY., September 30, 2014 – The Robarts Research Institute (Western University, London, ON) released a study demonstrating that, after 3 weeks of daily use, the Aerobika® device provides statistically significant outcomes in patients with Chronic Obstructive Pulmonary Disease (COPD) and Bronchiectasis. The study evaluated patients’ on Pulmonary Function Test, Six Minute Walk Test, the St. George’s Respiratory Questionnaire (SGRQ), the Patient Evaluation Questionnaire (PEQ) and Hyperpolarized Helium-3 Magnetic Resonance Lung Imaging (3He MRI). Patients’ improvements included increased mucus clearance, decreased cough frequency and breathlessness, and enhanced exercise tolerance. Additionally, the study revealed that patients reported an overall improvement in quality of life, without any adverse events reported while using the device.
- THE AEROBIKA® DEVICE, MARKETED BY MONAGHAN MEDICAL IN THE UNITED STATES, BENEFITS COPD PATIENTS AND WINS GOLD AT MDEA AWARDS
The Aerobika® Device, Marketed by Monaghan Medical in the United States, benefits COPD patients and wins Gold at MDEA Awards
PLATTSBURGH, NY., July 16, 2014: The Aerobika® Oscillating Positive Expiratory Pressure (OPEP) Therapy System has earned Gold at the Medical Design Excellence Awards (MDEA). MDEA is an International Award recognizing groundbreaking products that save lives, improve patient healthcare, change the face of medical technology, and overcome design and engineering challenges. It is one of the medical technology industry's highest honors.
- COMPARISON OF AEROSOL DRUG DELIVERY TO A NASO-PHARYNGEAL REPLICA VIA TWO VALVED HOLDING CHAMBERS (VHC) WITH FACEMASK VIA NEXT GENERATION CASCADE IMPAC
BACKGROUND: In vitro assessments of VHC performance are primarily designed to characterize aerosol formulations during product development and to ensure consistent product quality, rather than predict how the device will perform when used by a patient. In vivo, delivery is influenced by numerous factors, including device design, patient interface, patient compliance and airway anatomy. The use of casts of anatomical throats provides a means of reproducing the clinical situation more accurately. We report a
laboratory-based comparison of aerosol drug delivery between two VHCs using a cascade impactor and a replica infant face and naso-pharyngeal airway developed from computed tomography (CT) scans.
- COMPARISON OF AEROSOL DRUG DELIVERY TO A NASO-PHARYNGEAL REPLICA VIA TWO VALVED HOLDING CHAMBERS (VHC) WITH FACEMASK VIA BREATH SIMULATION
BACKGROUND: In order to improve patient compliance, the use of charge dissipative materials in VHC construction is becoming the standard of care. A facemask is required as the interface between patient and VHC for young children who cannot breathe through a mouthpiece. Recent studies have emphasized that a well-fitting facemask is critical for optimal drug delivery. We report a laboratory based comparison of aerosol drug delivery between two ‘antistatic’ VHCs under simulated breathing conditions, using a anatomically correct infant face-upper airway model (ADAM-III, Trudell Medical International (TMI)).
BPA exposure during late gestation accelerates secretory cell maturation in the proximal conducting airways. We identified a critical window of fetal susceptibility for BPA effects on lung epithelial cell maturation in the third trimester. This is of environmental health importance because increases in airway mucins are hallmarks of a number of childhood lung diseases that may be affected by BPA exposure.
There is increasing interest in fully breath-actuated nebulizers (BANs) (1) because of the following
- The delivery of medication can be optimized by the near elimination of exhaled aerosol that would otherwise be wasted;
- The risk of contamination of the local environment by exhaled aerosol with consequent caregiver exposure is greatly reduced or eliminated altogether;
- There is the potential for dosimetric delivery.
- COMBINING OSCILLATING POSITIVE EXPIRATORY PRESSURE THERAPY WITH INHALATION OF BRONCHODILATOR VIA A BREATH ACTUATED NEBULIZER
Secretion mobilization by Oscillating Positive Expiratory Pressure (OPEP) is often given separately to inhaled medication
- VERSATILITY OF A NEW REUSABLE BREATH ACTUATED NEBULIZER INTENDED FOR DOMICILIARY USE WITH ITS TABLE TOP COMPRESSOR
In the home-based situation, it can be helpful to be able to provide rapid bronchodilator therapy by nebulizer during exacerbations of obstructive lung disease
- COMBINING INHALATION BY A BREATH ACTUATED NEBULIZER WITH EXHALATION THROUGH AN OSCILLATING POSITIVE PRESSURE DEVICE OFFERS THE POTENTIAL FOR OPTIMAL C
To date Oscillating Positive Expiratory Pressure (OPEP) therapy to mobilize secretions and reduce dyspnea has been routinely given at a separate time to inhaled medical aerosol therapy